sigvotatug vedotin
mAbexperimentalADC
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Aug 21, 2024 (NCT06549816)
Timeline
Indications
Mechanism of action
- Integrin beta-6BINDING AGENT
Integrin beta-6 binding agent
- Integrin alpha-V/beta-6INHIBITOR
Integrin alpha-V/beta-6 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Payload
- vedotin
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314879 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07227298 | Phase 1/Phase 2 (Phase 2) | Nov 17, 2025 | Pfizer |
| NCT06758401 | Phase 3 | May 31, 2025 | Pfizer |
| NCT06549816 | Phase 1 | Aug 21, 2024 | Seattle Genetics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 2 | 2 | 2 | 2025 |
| Seattle Genetics | For profit | 1 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1